Journal
CANCER
Volume 116, Issue 14, Pages 3469-3476Publisher
JOHN WILEY & SONS INC
DOI: 10.1002/cncr.25297
Keywords
access to care; hematopoietic stem cell transplantation; effect of race and sex; leukemia; lymphoma
Categories
Funding
- National Cancer Institute (NCI) [U24-CA76518]
- National Heart, Lung and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- NHLBI [5U01HL069294]
- Health Resources and Services Administration (HRSA/DHHS) [HHSH234200637015C]
- Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
- AABB
- American Society for Blood and Marrow Transplantation
- Amgen, Inc
- Astellas Pharma US, Inc
- Baxter International, Inc
- Bayer HealthCare Pharmaceuticals
- Be the Match Foundation
- Biogen IDEC
- Bio-Marin Pharmaceutical, Inc
- Biovitrum AB
- BloodCenter of Wisconsin
- Blue Cross and Blue Shield Association
- Bone Marrow Foundation
- Canadian Blood and Marrow Transplant Group
- CaridianBCT
- Celgene Corporation
- CellGenix
- GmbH
- Centers for Disease Control and Prevention
- Children's Leukemia Research Association
- ClinImmune Labs
- CTI Clinical Trial and Consulting Services
- Cubist Pharmaceuticals
- Cylex Inc
- Cyto-Therm
- DOR BioPharma, Inc
- Dynal Biotech
- Invitrogen Company
- Eisai, Inc
- Enzon Pharmaceuticals, Inc
- European Group for Blood and Marrow Transplantation
- Gamida Cell, Ltd
- GE Healthcare
- Genentech, Inc
- Genzyme Corporation
- Histogenetics, Inc
- HKS Medical Information Systems
- Hospira, Inc
- Infectious Diseases Society of America
- Kiadis Pharma
- Kirin Brewery Co., Ltd
- Leukemia and Lymphoma Society
- Merck Company
- Medical College of Wisconsin
- MGI Pharma, Inc
- Michigan Community Blood Centers
- Millennium Pharmaceuticals, Inc
- Miller Pharmacal Group
- Milliman USA, Inc
- Miltenyi Biotec, Inc
- National Marrow Donor Program
- Nature Publishing Group
- New York Blood Center
- Novartis Oncology
- Oncology Nursing Society
- Osiris Therapeutics, Inc
- Otsuka America Pharmaceutical, Inc
- Pall Life Sciences
- Pfizer Inc
- Saladax Biomedical, Inc
- Schering Corporation
- Society for Healthcare Epidemiology of America
- StemCyte, Inc
- StemSoft Software, Inc
- Sysmex America, Inc
- Teva Pharmaceutical Industries
- THERAKOS, Inc
- Thermogenesis Corporation
- Vidacare Corporation
- Vion Pharmaceuticals, Inc
- ViraCor Laboratories
- ViroPharma, Inc
- Wellpoint, Inc
- Aetna
Ask authors/readers for more resources
BACKGROUND: The purpose of the current study was to determine whether the use of hematopoietic stem cell transplantation (HCT) to treat leukemia, lymphoma, or multiple myeloma (MM) differs by race and sex. METHODS: The annual incidence of leukemia, lymphoma, and MM was estimated in the United States in people aged <70 years by race and sex using the Surveillance, Epidemiology, and End Results (SEER) cancer registry between 1997 and 2002 and US census reports for the year 2000. The annual incidence of autologous, human leukocyte antigen (HLA) identical sibling, and unrelated HCT performed in these groups was estimated using Center for International Blood and Marrow Transplant Research data from 1997 through 2002. Logistic regression analysis was used to calculate the age-adjusted odds ratio (OR) of receiving HCT for Caucasians versus African Americans and for men versus women. RESULTS: The likelihood of undergoing HCT was found to be higher for Caucasians than for African Americans (OR, 1.40; 95% confidence interval [95% CI], 1.34-1.46). This difference existed for each type of HCT: autologous (OR, 1.24; 95% CI, 1.19-1.30), HLA identical sibling (OR, 1.59; 95% Cl, 1.46-1.74), and unrelated donor (OR, 2.02; 95% CI, 1.75-2.33). Overall, men were more likely than women to receive HCT (OR, 1.07; 95% CI, 1.05-1.1 [P <.0001]); however, this difference was found to be significant only for autologous HCT (OR, 1.10; 95% CI, 1.07-1.13 [P <.0001]). CONCLUSIONS: HCT is more frequently used to treat leukemia, lymphoma, and MM in Caucasians than in African American individuals. African Americans have lower rates of both autologous and allogeneic HCT, indicating that donor availability cannot fully explain the differences. Women are less likely than men to receive autologous HCT for reasons unexplained by age or disease status. Cancer 2010;116:3469-76. (C) 2010 American Cancer Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available